Artificial Intelligence
Mosaic Hires GoldSpot Discoveries to Work on the Gaboury Project
MONTREAL, June 23, 2022 (GLOBE NEWSWIRE) — Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces that it has hired GoldSpot Discoveries Corp. (TSX-V : SPOT), a leading technology company leveraging artificial intelligence and data science to transform the mineral discovery process, to apply its proprietary machine learning and geoscience expertise at the Gaboury Nickel Project in Témiscamingue, Québec.
Mosaic Minerals holds 6,064 hectares located approximately 150 km SW of the Rouyn-Noranda mining camp and 11 km East of the former Loraine Mine. The Gaboury project is a nickel-rich ultramafic intrusive, that potentially stretches over 9 km. GoldSpot will provide traditional regional targeting, 3D modelling, prospectivity mapping and Smart Targets for drilling using traditional and machine learning-assisted methods for these critical metals project.
Nickel has been primarily used in stainless steel production in the past but is now being used as one of the primary components in lithium-ion batteries. With the recent surge in electric vehicle (EV) production, nickel has seen an unprecedented surge in demand with companies such as Tesla entering into production contracts with nickel miners including mining giant Vale.
“GoldSpot is resource agnostic. We work in battery metals, base metals, silver, gold and diamonds among many other commodities,” Vincent Dubé-Bourgeois, CEO of GoldSpot commented. “Many people don’t realize that our proprietary methods can be applied across a broad range of mineralization types and commodities. The Gaboury Project is a great example of this. They have a highly prospective Nickel corridor that we will be applying our machine learning and traditional geoscience for Smart Targeting. I’m excited to be working with Mosaic Minerals and look forward to the outcomes of this project.”
“We are happy to work with GoldSpot Discoveries, a promising young Canadian company that brings an important technological aspect to our industry. We believe they can help us better conceptualize the potential of our flagship Gaboury property.” concluded Jonathan Hamel, Mosaic Minerals President and CEO.
Resignation of Director
The Company also announces the resignation of Mr. Jean Rainville from his role of Director of the Company effective immediately. Mr. Rainville has over 40 years of experience in the mining industry and financial markets. The Management wishes to thank Mr. Rainville for his valuable and dedicated services to the Company.
About Mosaic Minerals Corporation
Mosaic Minerals Corp. is a Canadian mining exploration company listed on the Canadian Securities Exchange (CSE: MOC) focusing on the exploration of strategic minerals in the territory of the province of Quebec.
Source :
M. Jonathan Hamel
President & CEO
[email protected]
514-317-7956
This release contains certain “forward-looking information” under applicable Canadian securities laws concerning the Arrangement. Forward-looking information reflects the Company’s current internal expectations or beliefs and is based on information currently available to the Company. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “projects”, “potential”, “scheduled”, “forecast”, “budget” or the negative of those terms or other comparable terminology. Assumptions upon which such forward-looking information is based includes, among others, that the conditions to closing of the Arrangement will be satisfied and that the Arrangement will be completed on the terms set out in the definitive agreement. Many of these assumptions are based on factors and events that are not within the control of the Company, and there is no assurance they will prove to be correct or accurate. Risk factors that could cause actual results to differ materially from those predicted herein include, without limitation: that the remaining conditions to the Arrangement will not be satisfied; that the business prospects and opportunities of the Company will not proceed as anticipated; changes in the global prices for gold or certain other commodities (such as diesel, aluminum and electricity); changes in U.S. dollar and other currency exchange rates, interest rates or gold lease rates; risks arising from holding derivative instruments; the level of liquidity and capital resources; access to capital markets, financing and interest rates; mining tax regimes; ability to successfully integrate acquired assets; legislative, political or economic developments in the jurisdictions in which the Company carries on business; operating or technical difficulties in connection with mining or development activities; laws and regulations governing the protection of the environment; employee relations; availability and increasing costs associated with mining inputs and labour; the speculative nature of exploration and development; contests over title to properties, particularly title to undeveloped properties; and the risks involved in the exploration, development and mining business. Risks and unknowns inherent in all projects include the inaccuracy of estimated reserves and resources, metallurgical recoveries, capital and operating costs of such projects, and the future prices for the relevant minerals. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Artificial Intelligence
Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third
PHILADELPHIA, May 8, 2024 /PRNewswire/ — Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship eCOA solution, TrialMax®. By leveraging process and technology enhancements, Signant’s operational teams can reduce the time it takes to go live with electronic patient-reported outcomes solutions by thirty percent or more.
Sponsors and Contract Research Organizations (CROs) have relied on Signant’s eCOA solution for over 20 years. The solution is known for its flexibility, reliability, scientific support, global logistics support, and ability to scale to any size trial, anywhere in the world. Traditionally, the time to bring the system live for patients and sites was commensurate with the operational complexity and trial design.
According to the company, customers can now benefit from this highly customizable eCOA solution along with Signant’s leading levels of science, scale, and service – delivered under much faster timelines.
“We are excited to offer customers the best of both worlds,” said Sanjiv Waghmare, Signant’s chief product officer. “They can get the fully featured, market-leading eCOA solution they already use and love, at a much faster pace. We believe this is especially meaningful as trial designs continue to increase in complexity. We want to ensure our customers hit their FPFV dates and start collecting high quality data without worrying about if their eCOA solution will be available.”
According to Waghmare, Signant’s engineering and operational teams identified areas where process enhancements and automation could dramatically reduce common implementation steps regardless of trial complexity. These steps cover all aspects of a typical eCOA timeline including study build, testing, translations, scale management, and validation.
“This is just the beginning of our efforts to deliver complexity at speed, with outstanding quality,” continued Waghmare. “We are also bringing additional efficiencies to our processes that will accelerate post-implementation support, including reporting, analytics, and data change management.”
Signant also offers a tenured solution for eCOA studies as part of its Signant SmartSignals® Unified Platform, which is fully integrated with EDC, RTSM, eConsent, and telemedicine. For more information about all Signant’s eClinical solutions, go to www.signanthealth.com.
About Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
Contact:
Heather [email protected]+1 610.400.4141
Logo – https://mma.prnewswire.com/media/1202052/Signant_Health_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/signant-health-extends-ecoa-leadership-position-through-operational-innovations-that-reduce-timelines-by-at-least-one-third-302138773.html
Artificial Intelligence
Ness Digital Engineering Acquires Intricity – a New York based company specializing in data strategy, governance, modernization, and monetization
NEW YORK, May 8, 2024 /PRNewswire/ — Ness Digital Engineering (Ness), a global full-lifecycle digital services transformation company, has acquired Intricity, a leading provider of data strategy, governance, modernization, and monetization solutions. The acquisition deepens Ness’s data offerings, which global F1000 clients have utilized to create new revenue streams and improve operating efficiencies.
“Ness has always had a strong capability in data engineering, and the acquisition of Intricity brings the data strategy and advisory capability. Furthermore, Ness will build on Intricity’s strategic alliances with Snowflake and Databricks,” said Ranjit Tinaikar, CEO, Ness Digital Engineering. “We are excited to welcome Intricity’s talented team to Ness, combining our strengths to deliver even greater value to our clients.”
Intricity brings deep expertise in handling complex data modernization and monetization problems that are the heart of any digital transformation today.
“Joining Ness, backed by KKR, presents an exciting opportunity to accelerate our growth trajectory worldwide. We are excited to leverage Ness’s global presence, digital competencies, and deep industry expertise to deliver digital transformation solutions to a wider range of clients,” said Arkady Kleyner, Principal & Co-Founder, Intricity. “Together, we are well-positioned to drive meaningful business outcomes and accelerate innovation for our clients.”
Commenting on the acquisition, Troy Clemente, Principal & Co-Founder, Intricity, added, “We have successfully established ourselves as experts covering the entire information lifecycle, and by joining Ness, we can accelerate our combined clients’ AI journeys based on modern data infrastructures.”
Zinnov acted as financial advisor to Ness Digital Engineering.
For more information:Tanaya Misra, Global Head – PR & [email protected]
About Ness Digital Engineering
Ness Digital Engineering, which funds managed by global investment firm KKR acquired in 2022, is a full-lifecycle digital engineering firm offering digital advisory through scaled engineering services. Headquartered in New York, Ness serves our customers across 11 innovation hubs in the US, Eastern Europe, and India. Combining our core competence in engineering with the latest in digital strategy and technology, we seamlessly manage Digital Transformation journeys from strategy through execution to help businesses thrive in the digital economy. For more information, visit www.ness.com.
Logo: https://mma.prnewswire.com/media/2144213/4406841/Ness_Blue_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ness-digital-engineering-acquires-intricity—a-new-york-based-company-specializing-in-data-strategy-governance-modernization-and-monetization-302139799.html
Artificial Intelligence
Körber Pharma and Siemens Take the Lead in ABI Research’s MES Software for Pharmaceutical, Biotechnology, and Cell & Gene Manufacturing Competitive Ranking
LONDON, May 8, 2024 /PRNewswire/ — The new Competitive Assessment by global technology intelligence firm ABI Research provides an in-depth and unbiased examination of the solutions offered by 13 manufacturing execution system (MES) software suppliers targeting pharmaceutical, biotech, and cell & gene manufacturing. The companies evaluated and ranked are:
Market Leaders: Körber Pharma, Siemens, Apprentice, Rockwell Automation, and TulipMainstream: Dassault Systèmes, GE Digital, Honeywell, Emerson, MPDV, MasterControl, ParsecFollowers: Sepasoft
“Overall, the MES software market for pharmaceutical, biotechnology, and cell & gene manufacturing is highly competitive, and the top innovators offer very comparable solutions. Technology vendors are aggressively developing new functionality, and competitors must closely watch and identify areas where they can match or leapfrog software capabilities,” explains James Prestwood, Industrial & Manufacturing Industry Analyst at ABI Research.
A total of ten overarching criteria were chosen for the purposes of this analysis and segmented across innovation and implementation clusters. These include how comprehensive the solution is and what innovative functionality it offers, data visibility, accessibility, and security within the platform, the user experience, and the capacity of worker augmentation, the MES’s contribution to manufacturers digital thread capabilities, and the alignment of the MES software with the pharmaceutical, biotechnology, and cell & gene manufacturing markets. In addition, the report evaluates MES vendor’s ability to deliver rapid time to value, their experience in delivering the software to manufacturers, the extensiveness of the vendor’s partnership base, the support for SME manufacturers, and the comprehensiveness of the software’s pricing options.
Körber Pharma and Siemens came out on top in the competitor ranking, with both firms scoring well across all criteria. Apprentice ranked as the top innovator in the assessment, offering a wide range of strong functionality designed specifically for life sciences manufacturing, an excellent cloud-native design, and comprehensive low/no-code capabilities. Dassault Systèmes scored particularly well in the implementation criteria, ranking second, with its center-of-excellence deployment model allowing manufacturers to quickly and consistently deploy and scale DELMIA Apriso.
“Pharmaceutical, biotech, and cell & gene manufacturing have been slow to embrace digital transformation but are now catching up. The industry’s strict regulations mean new solutions must be proven, and a premium should be placed on extensive deployment experiences when choosing solutions and technology partners,” Prestwood concludes.
These findings are from ABI Research’s MES Software for Pharmaceutical, Biotech, and Cell & Gene Therapy Manufacturing Competitive Ranking report. This report is part of the company’s Industrial and Manufacturing Markets research service, which includes research, data, and ABI Insights. Based on extensive primary interviews, Competitive Ranking reports offer comprehensive analysis of implementation and innovation strategies to offer unparalleled insight into a company’s performance and standing compared to its competitors.
About ABI Research
ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.
ABI Research是一家全球性的技术情报公司，拥有得天独厚的优势，充当终端市场公司和技术解决方案提供商之间的桥梁，通过提供独家研究和专业性指导，推动成功的技术实施和提供经证明可吸引和留住客户的战略，无缝连接这两大主体。
For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.
Contact Info:
GlobalDeborah Petrara Tel: +1.516.624.2558 [email protected]
Logo – https://mma.prnewswire.com/media/2309035/4693374/ABI_Research_2024.jpg
View original content:https://www.prnewswire.co.uk/news-releases/korber-pharma-and-siemens-take-the-lead-in-abi-researchs-mes-software-for-pharmaceutical-biotechnology-and-cell–gene-manufacturing-competitive-ranking-302139303.html
-
Artificial Intelligence5 days agoCleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Uncategorized6 days agoImproving the Developer Journey in Crafting Artificial Intelligence Applications
-
Uncategorized6 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence5 days ago5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence5 days agoBitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence6 days agoVirtual Assistant Market Size to Grow USD 8613.5 Million by 2030 at a CAGR of 22.3% | Valuates Reports
-
Artificial Intelligence5 days agoInnodisk Introduces iCAP Air: Advancing Air Quality Management through Autonomous Decision-Making
-
Artificial Intelligence5 days agoAppian Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining Platforms Report
